Name: tert-Butyl (3-(5-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamido)propyl)carbamate
SKU: BB 0278996
Availability: InStock

Description

This compounds has uses in synthesis of potential drug candidates and as a negative control in biochemicals assays.

Additional information

Qty	1 g, 10 mg, 100 mg, 500 mg

The invention relates to preparation of pyrazolopyridazines(I) for the treatment and prevention of cancer, inflammatory and autoimmune diseases. Compounds I wherein Hal is Cl, F, Br, etc.; X is an integer 0-5; R¹ is CN, CF₃, F, etc.; y is integer 0-5; R³ is H, C_1-6 alkyl, C_2-6 alkenyl, etc.; R⁴ is OH, NH₂, etc., are claimed. The invention also relates to methods for reducing risk of developing cancer, inflammatory and autoimmune diseases using compounds I in mono- and combination therapy.

Antibody and related antibody drugs for the treatment of malignancies have led to progress in targeted cancer therapy. Preparation of diverse antibody conjugates is critical for preclin. and clin. applications. However, precise control in tagging mols. at specific locations on antibodies is essential to preserve their native function. In this study, a synthetic boronic acid (BA)-tosyl initiator was used to trigger a glycan-directed modification of IgGs, and the obtained IgG macroinitiators allowed a growth of the poly N-isopropylacrylamide (PNIPAAm) chains specifically at Fc-domains. Therefore, the PNIPAAm chains are located away from the critical antigen-binding domains (Fab), which could reasonably prevent the loss of biol. activity after the attachment of polymer chains. According to the proposed strategy, a site-selectively modified antiCon A (Con A) antibody-PNIPAAm conjugate showed 6-times higher efficiency in the binding of targeted Con A antigen to a randomly conjugated anti-Con A antibody-PNIPAAm conjugate. In this study, we developed the first chem. strategy for the site-specific preparation of IgG-polymer conjugates with conserved biol. activity as well as intact glycan structures.

Property Name	Property Value	Reference
Molecular Weight	400.5	Computed by PubChem 2.1 (PubChem release 2021.05.07)
XLogP3-AA	1.1	Computed by XLogP3 3.0 (PubChem release 2019.06.18)
Hydrogen Bond Donor Count	4	Computed by Cactvs 3.4.6.11 (PubChem release 2019.06.18)
Hydrogen Bond Acceptor Count	5	Computed by Cactvs 3.4.6.11 (PubChem release 2019.06.18)
Rotatable Bond Count	11	Computed by Cactvs 3.4.6.11 (PubChem release 2019.06.18)
Exact Mass	400.21442669	Computed by PubChem 2.1 (PubChem release 2021.05.07)
Monoisotopic Mass	400.21442669	Computed by PubChem 2.1 (PubChem release 2021.05.07)
Topological Polar Surface Area	134 Å²	Computed by Cactvs 3.4.6.11 (PubChem release 2019.06.18)
Heavy Atom Count	27	Computed by PubChem
Formal Charge	0	Computed by PubChem
Complexity	538	Computed by Cactvs 3.4.6.11 (PubChem release 2019.06.18)
Isotope Atom Count	0	Computed by PubChem
Defined Atom Stereocenter Count	3	Computed by PubChem
Undefined Atom Stereocenter Count	0	Computed by PubChem
Defined Bond Stereocenter Count	0	Computed by PubChem
Undefined Bond Stereocenter Count	0	Computed by PubChem
Covalently-Bonded Unit Count	1	Computed by PubChem
Compound Is Canonicalized	Yes	Computed by PubChem (release 2019.01.04)

tert-Butyl (3-(5-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamido)propyl)carbamate

Description

Additional information

Useful Links

Services

Address

tert-Butyl (3-(5-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamido)propyl)carbamate

Description

Additional information

Related products

Methyl 6-((2-(1-methyl-2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)hexanoate

(E)-Methyl 3-(5-(6-methylpyridin-2-yl)pent-2-en-4-yn-2-yl)pyrrolidine-1-carboxylate

N-((4H-1,2,4-Triazol-3-yl)methyl)-5-chloro-1H-indole-2-carboxamide

3-(Difluoromethyl)-1-methyl-1H-pyrazole-5-carboxylic acid

Useful Links

Services

Address